Forwarding this announcement:
“Moving from Technical Operations to Serial Entrepreneur”
Brock Siegel, PhD
Director: Life Science Angels, Ruubix Inc., Moleculo Inc., Rapid Diagnostek Inc., San Francisco
Friday, January 25, 2013
11:00am* 1022 Life Sciences
Abstract/Bio: Dr Siegel is a veteran member of the life science community, who has specialized in commercializing research technology for bio-medical R&D applications. In particular, he focused on DNA sequencing systems and other life science tools, building operations, launching scalable businesses and acquiring new businesses in both research and regulated life sciences markets, including diagnostics and forensics. He has been a senior executive with Millipore, BioSearch, Applied Biosystems, Solexa, Illumina, Complete Genomics and Moleculo. He participated, by supplying his DNA at Celera Genomics, in the first human genome sequenced.
Academically trained in bio-organic chemistry, Dr Siegel focused on the elucidation of enzyme mechanisms via synthetic organic model systems, an early entry into Synthetic Biology. He holds a Bachelor of Science from Syracuse University, a PhD in Chemistry from the University of Illinois, completed his post-doctoral work at Columbia University, and is a former Professor at the University of Minnesota.
Currently, Dr Siegel is an investment member of Life Science Angels, where he is also on the Board of Directors and co-chairs the Device Screening Group. He is an investment advisor at NEW Capital Fund LP, serves on the Board of Directors of Rapid Diagnostek Inc and the Addario Lung Cancer Medical Institute, the Advisory Boards of Ruubix Diagnostics Inc, Moleculo Sequencing Inc and the Board of Visitors at Syracuse University. He mentors young founders in the Burrill-UCSF “Ideas to IPO” program and is an investment advisor at UCSF’s QB3 Mission Bay Capital Fund. He has been named a Distinguished Alumni by the University of Illinois.